Price has memory, 100-106 area is particularly painful for anyone who got in this stock.
As you can see in the yellow box, Gilead spent a month in that range, many people wanted to play for a box/sym tri breakout and ride the "year-end beta chase/Santa Rally" (whatever the fvck that is, some kind of "conventional wisdom" CNBC had planted in newbie traders' brain...
Yes, yes, I know, this is now longer even a growth story, it's a value play. It has a very low multiple comparing to its peers. I'm sure it has a lot more room to run in the future. But right now, it looks like a sweet short from here.
SPY and QQQ all looking like an island today, yeah, maybe bulls will eventually get their 2000, but not this week. Moving room gettin' squeezed here, chances favor a down move.
Why is it 130d ma not 100d? I looked at 100d ma and felt it's been breached too easily too many times in the past, so I slowly increased the input calue and voila, for SPY, 130 is the new 100.
For some reason, I think REGN is gonna receive a positive reaction like BIIB did with its earnings. They are both overshadowed by the glamor of of CELG and GILD, which is an important ingredient of the surprise factor. It's always the quiet little guy that surprises people.
Given how Google's stock reacted after its earning, I'm getting very bullish on FB. People's willingness to pile in after the ER indicates that the risk taking crowd is back.
Let's hope it doesn't run past 70 before ER, so it has more room to run after the ER. If it gets too crazy before Wednesday, then I would probably trim back a little.
Again, a surprisingly...
A solid company, why it got left behind from the recovery is beyond my understanding. But it has been very predictable since the what will be known as the 2014 Biotech Selloff. PT is 340, 316ish is a very good support.
It got beaten so badly because of some analyst's note saying that REGN's blockbuster eye drug Eylea has been replaced by cheaper rival drugs. First, it was only rumored to be "10%" of total patients, secondly, its rheumatoid arthritis drug "sarilumab" that is under development with Sanofi is showing promising signs and is now in phase 3. Overall, reaction is a...
It's time for a pullback, a minor one, won't be more than 5%. It'll probably bounce from 155ish, complete the right shoulder, while the whole biotech sector taking a breather (BIIB jumped from 280 to 320, GILD climbed 20% in 2 months), then we'll make some all time highs.
I just don't buy the argument that the organic food industry is too saturated and competitive for Whole Foods to remain relevant. There's just so many people out there, the market is big enough for all the players to book profit and prosper.
Don't know much about the company, except that it held pretty nicely even when the whole sector is in a pullback mode today, probably just because it's too oversold. If you wanna swing a bounce, go for it. Any positive sign from the market will probably send UTHR above the 100 MA and break the neckline.
If not, well then there's always that 200 MA.
Boy, does VRX have shtty fundamental, but interesting technicals. I used to hate geometry when I was in high school, but it looks like it finally paid off.
I used dotted line to visualize the way that VRX could've gone if the Allergan deal doesn't exist.
VRX rallied 1000% in the last 4 years, the Allergan deal is like a life support machine for Valeant right...
